Antibody-drug conjugates have proven to be a versatile and effective tool in treating a wide range of tumor types, establishing the drug class as a valuable weapon against cancer. The approval of agents targeting various extracellular antigens associated with tumorigenesis continues to transform the treatment paradigm for a plethora of oncology indications. The late-phase pipeline is particularly active and promising. This Special Topics report provides a comprehensive market forecast of current and emerging antibody-drug conjugates in select oncology indications and analyzes key market trends and dynamics.
QUESTIONS ANSWERED
- What is the current landscape for approved antibody-drug conjugates? What are their approval timelines?
- What is the market positioning of emerging antibody-drug conjugates?
- How will the indication-specific market trends and dynamics evolve?
- What is the commercial potential of current and emerging antibody-drug conjugates by brand, indication, and geography? How will the market evolve over the 2022-2032 forecast period?
GEOGRAPHIES
United States, EU5, Japan.
EPIDEMIOLOGY
Drug-treated patient populations by brand, indication, combination type, and geography for indications for which antibody-drug conjugates are approved or forecast for approval.
FORECAST
10-year, annualized, drug-level sales of antibody-drug conjugates through 2031, segmented by indication, combination type, and geography.
KEY DRUGS COVERED
Select approved therapies (e.g., Enhertu, Kadcyla, Trodelvy, Polivy) and select emerging therapies expected to gain approval.
EMERGING THERAPIES
Agents in Phase 3 development.
PRODUCT DESCRIPTION
Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the antibody-drug conjugate landscape in relevant oncology indications.
Marcos Fernu00e1ndez Alfara
Marcos Fernández Alfara, M.Sc., Ph.D., Healthcare Research & Data Analyst, Oncology. Dr. Fernández has extensive experience in oncology, with a focus on novel immunotherapies for solid tumors. As part of his doctorate, he developed new strategies to boost immune responses against cancer cells. He obtained his master of science degree in cancer and stem cells from Utrecht University and his doctorate in biomedicine from the Institute for Research in Biomedicine at Barcelona University.
Julia Morris, Ph.D.
Julia Morris, Ph.D., Healthcare Research & Data Analyst, Oncology. Before joining Clarivate, she was a senior bioscientist in the Drug Discovery Unit at Cancer Research UK Manchester Institute. During this time, she developed and conducted assays to assess the effect of preclinical small-molecule inhibitors on in vitro cellular proliferation in breast, ovarian, and uterine cancer cell lines. She earned her Ph.D. in molecular biology from the University of Sheffield and a B.Sc in cellular and molecular medicine with study in industry from the University of Bristol.